Materials and methods for reduction of protein tau and treatment of neurodegenerative diseases

Patent metadata

Field	Value
Publication number	US-8940945-B2
Application number	US-201113810362-A
Country	US
Kind code	B2
Filing date	Jul 25, 2011
Priority date	Jul 23, 2010
Publication date	Jan 27, 2015
Grant date	Jan 27, 2015

Abstract

The subject invention provides a myricanol compound that is in predominant form of (+)-αR,11S-myricanol as compared to (−)-αS,11R-myricanol. In one embodiment, the (+)-αR,11S-myricanol is isolated from Myrica cerifera , and is in about 86% enantiomeric excess of (−)-αS,11R-myricanol. The subject invention also pertains to therapeutic compositions and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. Specifically exemplified herein is the therapeutic use of myricanol and myricanone isolated from root barks of Myrica species. Also provided are methods for preparing extracts of the subject invention from Myrica species.

First claim

What is claimed is:

1. A method of preparing a Myrica extract comprising myricanol, comprising:
a) providing a sufficient quantity of raw material of a Myrica species;
b) extracting the raw material with toluene to yield a toluene fraction and a first residue;
c) mixing the first residue with ethanol to yield an ethanol fraction and a second residue;
d) mixing the second residue with CMT buffer comprising about 30% chloroform, 10% methanol and 0.002% trifluoroacetic acid (TFA) to obtained a CMT extract; and
e) fractionating the CMT extract using MPLC and recovering the fraction that comprises myricanol.

2. The method of claim 1 , wherein the myricanol is in predominant form of (+)-αR,11S-myricanol as compared to (−)-αS,11R-myricanol, wherein the (±)-αR,11S form is in at least 10% enantiomeric excess of the (−)-αS,11R foam.

3. The method of claim 2 , wherein the (+)-αR,11S form is in about 86% enantiomeric excess of the (−)-αS,11R form.

Assignees

• Dickey Chad
• Lebar Matthew
• Baker Bill J
• Jones Jeffrey
• Univ South Florida

Inventors

• Dickey Chad
• Lebar Matthew
• Baker Bill J
• Jones Jeffrey

Classifications

• C07C43/196

  containing hydroxy or O-metal groups · CPC title

• C07B2200/07

  Optical isomers · CPC title

• A61K31/09

  having two or more such linkages · CPC title

• C07C2603/92

  with a condensed ring system consisting of at least two mutually uncondensed aromatic ring systems, linked by an annular structure formed by carbon chains on non-adjacent positions of the aromatic system, e.g. cyclophanes · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title